目的 观察痰热清注射液联合吸入用丙酸倍氯米松混悬液治疗儿童喘息性支气管炎的临床疗效。方法 选取2016年12月—2018年7月在驻马店市中心医院治疗的喘息性支气管炎患儿100例作为研究对象，采用数字表法将患儿随机分为对照组和治疗组，每组各50例。对照组雾化吸入用丙酸倍氯米松混悬液，0.5支/次，1～2次/d。治疗组患儿在对照组治疗的基础上静脉滴注痰热清注射液，0.3～0.5 mL/kg加入到5%葡萄糖注射液100～250 mL中，1次/d。两组均连续治疗5 d。观察两组患者的临床疗效，同时比较两组治疗前后的临床症状消失时间、肺功能指标、血清学指标。结果 治疗后，对照组和治疗组的总有效率分别为78.0%、92.0%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组患儿的咳嗽消失时间、喘息消失时间、肺部啰音消失时间、气促缓解时间和退热时间均显著短于对照组，两组比较差异具有统计学意义（P<0.05、0.01）。治疗后，对照组的用力肺活量（FVC）、用力呼吸容积（FEV₁）、FVC/FEV₁、最大呼气流量（PEF）、肺活量（VC）和最大通气量（MVV）水平均明显上升，呼出气一氧化氮（FeNO）明显下降，同组治疗前后比较差异具有显著性（P<0.05）；治疗组的FEV₁、FVC/FEV₁和MVV水平上升，且同组治疗前后比较具有显著差异（P<0.05），FVC、PEF、VC水平上升，FeNO下降，同组治疗前后比较具有极显著性差异（P<0.01）。治疗后，治疗组患儿的肺功能指标明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患儿的白细胞介素-8（IL-8）、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组血清学指标显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 痰热清注射液联合丙酸倍氯米松混悬液治疗喘息性支气管炎具有较好的临床疗效，可明显缩短临床症状恢复时间，降低血清炎症因子水平，改善肺功能，具有一定的临床推广价值。

Objective To observe the clinical efficacy of Tanreqing Injection combined with Beclometasone Dipropionate Suspension for inhalation in treatment of asthmatic bronchitis in children. Methods Children (100 cases) with asthmatic bronchitis in Zhumadian Central Hospital from December 2016 to July 2018 were randomly divided into control and treatment groups, each group had 50 cases. Children in the control group were aerosol inhalation administered with Beclometasone Dipropionate Suspension for inhalation, 0.5 tube/time, 1-2 times/d. Children in the treatment group were iv administered with Tanreqing Injection, 0.3-0.5 mL/kg added into 5% Glucose Injection 100-250 mL, once daily. Children in two groups were treated for 5 d. After treatment, the clinical efficacy was evaluated, and the disappearing times of clinical symptom, lung function indexes, and serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 78.0% and 92.0%, respectively, and there were differences between two groups (P<0.05). After treatment, the cough disappearance time, wheezing disappearance time, lung rale disappearance time, shortness of breath relief time, and fever clearance time in the treatment group was significantly shorter than those in the control group, with significant difference between two groups (P<0.05, 0.01). After treatment, FVC, FEV₁, FVC/FEV₁, PEF, VC, and MVV in the control group were significantly increased, but FeNO was decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the levels of FEV₁, FVC/FEV₁, and MVV in the treatment group were increased, and the difference was statistically significant in the same group (P<0.05). And the levels of FVC, PEF, and VC in the treatment group were increased, but FeNO was decreased, and the difference was extremely significant in the same group (P<0.01). After treatment, the lung function indexes in the treatment group were significantly better than those in the control group, and there were differences between two groups (P<0.05). After treatment, the levels of IL-8, IL-6, and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, serological indexes in the treatment group were significantly lower than those in the control group, and there were differences between two groups (P<0.05).Conclusion Tanreqing Injection combined with Beclometasone Dipropionate Suspension for inhalation has good clinical curative effect in treatment of asthmatic bronchitis in children, can obviously shorten the recovery time of clinical symptoms, reduce serum inflammatory factors levels, and improve lung function, which has a certain clinical application value.